Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery

Xiangmin Lin; Min Shi; Jeyaraj Gunasingh Masilamoni; Romel Dator; James Movius; Patrick Aro; Yoland Smith; Jing Zhang

doi:10.1016/j.bbapap.2015.01.007

Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery

Xiangmin Lin, Min Shi, Jeyaraj Gunasingh Masilamoni, Romel Dator, James Movius, Patrick Aro, Yoland Smith, Jing Zhang

Carcinogenesis and Chemoprevention

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Identification of reliable and robust biomarkers is crucial to enable early diagnosis of Parkinson disease (PD) and monitoring disease progression. While imperfect, the slow, chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced non-human primate animal model system of parkinsonism is an abundant source of pre-motor or early stage PD biomarker discovery. Here, we present a study of a MPTP rhesus monkey model of PD that utilizes complementary quantitative iTRAQ-based proteomic, glycoproteomics and phosphoproteomics approaches. We compared the glycoprotein, non-glycoprotein, and phosphoprotein profiles in the putamen of asymptomatic and symptomatic MPTP-treated monkeys as well as saline injected controls. We identified 86 glycoproteins, 163 non-glycoproteins, and 71 phosphoproteins differentially expressed in the MPTP-treated groups. Functional analysis of the data sets inferred the biological processes and pathways that link to neurodegeneration in PD and related disorders. Several potential biomarkers identified in this study have already been translated for their usefulness in PD diagnosis in human subjects and further validation investigations are currently under way. In addition to providing potential early PD biomarkers, this comprehensive quantitative proteomic study may also shed insights regarding the mechanisms underlying early PD development. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.

Original language	English (US)
Pages (from-to)	779-787
Number of pages	9
Journal	Biochimica et Biophysica Acta - Proteins and Proteomics
Volume	1854
Issue number	7
DOIs	https://doi.org/10.1016/j.bbapap.2015.01.007
State	Published - Jul 1 2015

Bibliographical note

Funding Information:
This study was supported by generous grants from the National Institutes of Health (NIH) ( R01 NS057567 , U01 NS082137 , P50 NS062684-6221 , P30 ES007033-6364 , R01 AG033398 , R01 ES016873 , and R01 ES019277 to JZ). It was also supported in part by the University of Washington's Proteomics Resource ( UWPR95794 ), a NIH infrastructure grant to the Yerkes National Primate Research Center ( P51 OD011132 ), the Emory UDALL Center of Excellence for Parkinson's Disease ( P50 NS071669 ), and the National Natural Science Foundation of China (NSFC) projects ( 31200105 and 31470238 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors.

Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.

Keywords

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Glycoproteomics
Macaca mulatta
Parkinson disease
Phosphoproteomics
Putamen

Access

10.1016/j.bbapap.2015.01.007

OpenUrl availability

Full text

Cite this

@article{93829cc818234639a002c13b6fa8d629,

title = "Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery",

abstract = "Identification of reliable and robust biomarkers is crucial to enable early diagnosis of Parkinson disease (PD) and monitoring disease progression. While imperfect, the slow, chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced non-human primate animal model system of parkinsonism is an abundant source of pre-motor or early stage PD biomarker discovery. Here, we present a study of a MPTP rhesus monkey model of PD that utilizes complementary quantitative iTRAQ-based proteomic, glycoproteomics and phosphoproteomics approaches. We compared the glycoprotein, non-glycoprotein, and phosphoprotein profiles in the putamen of asymptomatic and symptomatic MPTP-treated monkeys as well as saline injected controls. We identified 86 glycoproteins, 163 non-glycoproteins, and 71 phosphoproteins differentially expressed in the MPTP-treated groups. Functional analysis of the data sets inferred the biological processes and pathways that link to neurodegeneration in PD and related disorders. Several potential biomarkers identified in this study have already been translated for their usefulness in PD diagnosis in human subjects and further validation investigations are currently under way. In addition to providing potential early PD biomarkers, this comprehensive quantitative proteomic study may also shed insights regarding the mechanisms underlying early PD development. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.",

keywords = "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Glycoproteomics, Macaca mulatta, Parkinson disease, Phosphoproteomics, Putamen",

author = "Xiangmin Lin and Min Shi and Masilamoni, {Jeyaraj Gunasingh} and Romel Dator and James Movius and Patrick Aro and Yoland Smith and Jing Zhang",

note = "Funding Information: This study was supported by generous grants from the National Institutes of Health (NIH) ( R01 NS057567 , U01 NS082137 , P50 NS062684-6221 , P30 ES007033-6364 , R01 AG033398 , R01 ES016873 , and R01 ES019277 to JZ). It was also supported in part by the University of Washington's Proteomics Resource ( UWPR95794 ), a NIH infrastructure grant to the Yerkes National Primate Research Center ( P51 OD011132 ), the Emory UDALL Center of Excellence for Parkinson's Disease ( P50 NS071669 ), and the National Natural Science Foundation of China (NSFC) projects ( 31200105 and 31470238 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. Publisher Copyright: {\textcopyright} 2015 Elsevier B.V. All rights reserved.",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.bbapap.2015.01.007",

language = "English (US)",

volume = "1854",

pages = "779--787",

journal = "Biochimica et Biophysica Acta - Proteins and Proteomics",

issn = "1570-9639",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery

AU - Lin, Xiangmin

AU - Shi, Min

AU - Masilamoni, Jeyaraj Gunasingh

AU - Dator, Romel

AU - Movius, James

AU - Aro, Patrick

AU - Smith, Yoland

AU - Zhang, Jing

N1 - Funding Information: This study was supported by generous grants from the National Institutes of Health (NIH) ( R01 NS057567 , U01 NS082137 , P50 NS062684-6221 , P30 ES007033-6364 , R01 AG033398 , R01 ES016873 , and R01 ES019277 to JZ). It was also supported in part by the University of Washington's Proteomics Resource ( UWPR95794 ), a NIH infrastructure grant to the Yerkes National Primate Research Center ( P51 OD011132 ), the Emory UDALL Center of Excellence for Parkinson's Disease ( P50 NS071669 ), and the National Natural Science Foundation of China (NSFC) projects ( 31200105 and 31470238 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. Publisher Copyright: © 2015 Elsevier B.V. All rights reserved.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Identification of reliable and robust biomarkers is crucial to enable early diagnosis of Parkinson disease (PD) and monitoring disease progression. While imperfect, the slow, chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced non-human primate animal model system of parkinsonism is an abundant source of pre-motor or early stage PD biomarker discovery. Here, we present a study of a MPTP rhesus monkey model of PD that utilizes complementary quantitative iTRAQ-based proteomic, glycoproteomics and phosphoproteomics approaches. We compared the glycoprotein, non-glycoprotein, and phosphoprotein profiles in the putamen of asymptomatic and symptomatic MPTP-treated monkeys as well as saline injected controls. We identified 86 glycoproteins, 163 non-glycoproteins, and 71 phosphoproteins differentially expressed in the MPTP-treated groups. Functional analysis of the data sets inferred the biological processes and pathways that link to neurodegeneration in PD and related disorders. Several potential biomarkers identified in this study have already been translated for their usefulness in PD diagnosis in human subjects and further validation investigations are currently under way. In addition to providing potential early PD biomarkers, this comprehensive quantitative proteomic study may also shed insights regarding the mechanisms underlying early PD development. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.

AB - Identification of reliable and robust biomarkers is crucial to enable early diagnosis of Parkinson disease (PD) and monitoring disease progression. While imperfect, the slow, chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced non-human primate animal model system of parkinsonism is an abundant source of pre-motor or early stage PD biomarker discovery. Here, we present a study of a MPTP rhesus monkey model of PD that utilizes complementary quantitative iTRAQ-based proteomic, glycoproteomics and phosphoproteomics approaches. We compared the glycoprotein, non-glycoprotein, and phosphoprotein profiles in the putamen of asymptomatic and symptomatic MPTP-treated monkeys as well as saline injected controls. We identified 86 glycoproteins, 163 non-glycoproteins, and 71 phosphoproteins differentially expressed in the MPTP-treated groups. Functional analysis of the data sets inferred the biological processes and pathways that link to neurodegeneration in PD and related disorders. Several potential biomarkers identified in this study have already been translated for their usefulness in PD diagnosis in human subjects and further validation investigations are currently under way. In addition to providing potential early PD biomarkers, this comprehensive quantitative proteomic study may also shed insights regarding the mechanisms underlying early PD development. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.

KW - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

KW - Glycoproteomics

KW - Macaca mulatta

KW - Parkinson disease

KW - Phosphoproteomics

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=84939990171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939990171&partnerID=8YFLogxK

U2 - 10.1016/j.bbapap.2015.01.007

DO - 10.1016/j.bbapap.2015.01.007

M3 - Article

C2 - 25617661

AN - SCOPUS:84939990171

SN - 1570-9639

VL - 1854

SP - 779

EP - 787

JO - Biochimica et Biophysica Acta - Proteins and Proteomics

JF - Biochimica et Biophysica Acta - Proteins and Proteomics

IS - 7

ER -

Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this